# Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

> **NCT01957280** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 17 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** patritumab

## Key facts

- **NCT ID:** NCT01957280
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-10
- **Final completion:** 2014-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957280, "Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01957280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*